Report Overview
Summary
Rigel Pharmaceuticals, Inc. (Rigel) is a clinical-stage biotechnology company that discovers and develops innovative small-molecule drugs for patients with immune disorders, hematological disorders, cancer and rare diseases. Its research activities focus on signaling pathways that are critical to disease mechanisms. The company’s clinical programs include clinical trials of fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in various indications. Rigel submitted an NDA to the US FDA for fostamatinib in patients with chronic or persistent immune thrombocytopenia (ITP). Fostamatinib is also being developed for autoimmune hemolytic anemia and IgA nephropathy. Rigel is headquartered in South San Francisco, California, the US.
Rigel Pharmaceuticals Inc (RIGL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Rigel Enters into R&D Agreement with Bristol-Myers Squibb for TGF Beta Receptor Kinase Inhibitors 11
Proteros Biostructures Extends Collaboration With Rigel Pharma 12
Licensing Agreements 13
Aclaris Therapeutics International Enters into Licensing Agreement with Rigel Pharma 13
Rigel Pharma Enters Into Licensing Agreement With BerGenBio For BGB324 14
Equity Offering 16
Rigel Pharma to Raise USD40 Million in Public Offering of Shares 16
Rigel Pharma Raises USD46 Million in Public Offering of Shares 17
Rigel Pharma to Raise up to USD30 Million in Private Placement of Shares 19
Rigel Pharma Completes Public Offering Of Shares For US$145 Million 20
Rigel Pharma Completes An Underwritten Public Offering Of US$130.4 Million 22
Rigel Pharmaceuticals Inc - Key Competitors 24
Rigel Pharmaceuticals Inc - Key Employees 25
Rigel Pharmaceuticals Inc - Locations And Subsidiaries 26
Head Office 26
Recent Developments 27
Financial Announcements 27
Aug 01, 2017: Rigel Announces Second Quarter 2017 Financial Results and Provides Company Update 27
May 02, 2017: Rigel Announces First Quarter 2017 Financial Results and Provides Company Update 29
Mar 07, 2017: Rigel Announces Fourth Quarter 2016 and Year End 2016 Financial Results 31
Nov 01, 2016: Rigel Announces Third Quarter 2016 Financial Results and Provides Company Update 33
Aug 02, 2016: Rigel Announces Second Quarter 2016 Financial Results and Provides Portfolio Update 35
May 03, 2016: Rigel Announces First Quarter 2016 Financial Results 38
Mar 08, 2016: Rigel Announces Fourth Quarter and Year End 2015 Financial Results 39
Corporate Communications 40
Mar 08, 2016: Rigel Names Anne-Marie Duliege, M.D., M.S. As Chief Medical Officer 40
Product News 41
09/15/2016: Rigel Restructures to Focus on Fostamatinib Commercialization 41
04/12/2016: Rigel Announces Presentation on AMPK preclinical research project at Upcoming American Association of Cancer Research (AACR) Conference 42
04/12/2016: Rigel Announces Presentation on preclinical research project R191 at Upcoming American Association of Cancer Research (AACR) Conference 43
01/30/2017: Fostamatinib Study Results Continue to Trend Positive 44
01/07/2016: Rigel Reviews Recent Progress and Announces Presentation at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco 45
Product Approvals 46
Apr 27, 2017: Rigel Announces Tavalisse as Proprietary Name for Fostamatinib in the United States 46
Apr 17, 2017: Rigel Submits New Drug Application to FDA for Fostamatinib in Chronic ITP 47
Clinical Trials 48
Oct 20, 2016: Rigel Announces Results from the Second FIT Phase 3 Study and the Long-Term Open-Label Extension Study for Fostamatinib in ITP 48
Aug 30, 2016: Rigel Fostamatinib Meets Primary Endpoint in Phase 3 Study in Chronic ITP 50
Apr 01, 2016: Rigel Completes Enrollment of FIT Phase 3 Program for Fostamatinib in ITP 52
Feb 25, 2016: Rigel Initiates Phase II Clinical Trial Of Fostamatinib In Autoimmune Hemolytic Anemia 53
Jan 28, 2016: Rigel Completes Enrollment of First Phase 3 Study of Fostamatinib in ITP 54
Appendix 55
Methodology 55
About GlobalData 55
Contact Us 55
Disclaimer 55
List of Tables
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Rigel Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Rigel Enters into R&D Agreement with Bristol-Myers Squibb for TGF Beta Receptor Kinase Inhibitors 11
Proteros Biostructures Extends Collaboration With Rigel Pharma 12
Aclaris Therapeutics International Enters into Licensing Agreement with Rigel Pharma 13
Rigel Pharma Enters Into Licensing Agreement With BerGenBio For BGB324 14
Rigel Pharma to Raise USD40 Million in Public Offering of Shares 16
Rigel Pharma Raises USD46 Million in Public Offering of Shares 17
Rigel Pharma to Raise up to USD30 Million in Private Placement of Shares 19
Rigel Pharma Completes Public Offering Of Shares For US$145 Million 20
Rigel Pharma Completes An Underwritten Public Offering Of US$130.4 Million 22
Rigel Pharmaceuticals Inc, Key Competitors 24
Rigel Pharmaceuticals Inc, Key Employees 25
List of Figures
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Rigel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9